ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Investigator: Maen Abdelrahim, MD

Study Coordinator: Michelle Guthrie

Status: Enrolling Number: NCT02264613

Phone: 713.441.6564

Protocol Number: Pro00017595


Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typeTP53.
More to Explore
Live Chat Available